Ripple Effects of the Patent Cliff

ProcureCon Pharma was last week in Philadelphia, and Source One was proud to be a sponsor of the event. With their history of partnering with major pharmaceutical companies, Source One was enthusiastic to attend and share their industry experience. This event has sparked us to consider some of the major issues facing pharma today—most notably, the ripple effects from the patent cliff that have left many organizations reeling.

There have been many changes since big pharma’s major brands have started to go off patent. However, the most notable differences, from a procurement perspective, involve indirect spend management, increased competition, mergers and acquisitions, uptick in biopharmaceuticals and even investments into emerging markets such as Africa. The infographic below explains some of these post-patent trends and their subsequent results.

Visit pharma.sourceoneinc.com to learn more.